Balderton Capital and Pentland Ventures led the round, with new investors Norrsken VC and JamJar Investments joining, too. Other investors included True, Italian Founders Fund, Athletico Ventures, SOLO Investments and Exceptional Ventures. The funding brings the company’s total backing to $32 million.
London-based Sava plans to use funds to accelerate regulatory approval and commercialization efforts for its next-generation wearable. It also expects to further expand its team of more than 60 people and advance automated manufacturing capabilities while accelerating the clinical validation of its technology.
The company develops a multi-molecule biosensor capable of detecting biomarkers just beneath the skin in real-time. This proprietary technology powers the company’s first product, a pain-free continuous glucose monitor (CGM). The CGM — already demonstrating promising early clinical results — streamlines molecular insights in real-time to a user’s phone.
Sava said its latest clinical trial, conducted independently by third-party investigators in the UK, involves 50 patients with type 1 and insulin-dependent type 2 diabetes. Early results from the first 25 patients demonstrated reliable, accurate glucose readings for up to 10 days of continuous wear, Sava said. The company says most microsensor systems “fail to last five days, and many struggle beyond 24 hours.”
Results from this trial provide a foundation for future regulatory submissions and a pivotal study set for the coming year.
Sava says that its multi-analyte sensing platform can go beyond glucose tracking, too, potentially detecting additional molecules. The company hopes to bring its sensor to biomarker monitoring across multiple disciplines.
Commentary from Sava officials
Rafaël Michali, co-founder and co-CEO of Sava, said: “This clinical trial marks a pivotal moment not just for Sava, but for the future of biosensing and personalized healthcare. The data generated so far has shown that our technology has the potential to match the performance of leading CGMs in the market today, without the invasiveness or high cost of filament-based systems. It paves the way for a completely novel approach to biosensing that can redefine the way we approach not only chronic disease management, but any health goal.”
Renato Circi, co-founder and co-CEO of Sava, said: “Glucose is only the beginning. We have built a modular platform, capable of multi-molecule sensing. New molecules will create new use cases. What we’re building here is not just a device, but a whole new technological foundation for personalized healthcare, where anyone can use a biosensor to understand their health in real-time, at a molecular level.”
